Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersPsychiatry Physician in Orange, CA
NPI: 1174589642Primary Practice Location
Advantage Neuropsychiatric Assoc
1010 W Chapman Ave, Orange, CA
Primary Employer
Advantage Neuropsychiatric Assoc
advantagepsyc.com
HQ Phone
Get M.D. Daniel's Phone Numberphone_androidMobile
Get M.D. Daniel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1990 - 2026
American Board of Psychiatry and Neurology
Psychiatry
University of California (Irvine)
Residency • Psychiatry
1989 - 1993
Jacobs School of Medicine and Biomedical Sciences
medicine.buffalo.edu
Medical School
Until 1989
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99308Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | 501 | 1,328 |
| 2 | 99306Initial nursing facility visit, typically 45 minutes per day | 413 | 414 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 243 | 1,701 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 147 | 163 |
| 5 | 99348Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | 75 | 362 |
Lead Sponsor: Luye Pharma Group Ltd.
Intervention / Treatment: DRUG: LY03010 351 mg treatment group, gluteal, DRUG: LY03010 156 mg treatment group, deltoid, DRUG: LY03010 156 mg treatment group, gluteal, DRUG: LY03010 351 mg treatment group, deltoid
Lead Sponsor: Shire
Intervention / Treatment: DRUG: Placebo, DRUG: SHP465
Lead Sponsor: Luye Pharma Group Ltd.
Intervention / Treatment: DRUG: Risperdal® Consta®, DRUG: LY03004
